Discover
GLSI
Greenwich LifeSciences, Inc.
23.70
2 x 17.36
2 x 29.79
bid
ask
+
0.24
1.02%
2 @ 04:00 PM
23.03 -0.67 (2.81%)
| Ytd | 12.80% | |
| 1y | 161.88% |
22.86
day range
24.50
7.78
52 week range
34.10
| Open | 23.51 | Prev Close | 23.46 | Low | 22.86 | High | 24.50 | Mkt Cap | 347.87M |
| Vol | 84.79K | Avg Vol | 141.89K | EPS | -1.61 | P/E | N/A | Forward P/E | -14.83 |
| Beta | 3.32 | Short Ratio | 21.41 | Inst. Own | 8.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 24.15 | 200-d Avg | 19.64 | 1yr Est | 38.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.21 | -0.2 | 0.01 | 4.76% |
| 2024-08-14 | 2024-06 | -0.2 | -0.2 | N/A | N/A |
| 2024-08-14 | 2024-06 | -0.2 | N/A | N/A | N/A |
| 2024-05-20 | 2024-03 | -0.2 | -0.19 | 0.01 | 5.00% |
| 2024-05-20 | 2024-03 | -0.2 | N/A | N/A | N/A |
| 2024-04-15 | 2023-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-02-28 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-02-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-04-10 | HC Wainwright & Co. | Upgrade | Buy | |
| 2021-09-01 | HC Wainwright & Co. | Upgrade | Buy |
Profile
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-25 | PATEL SNEHAL | Chief Executive Officer | 5.54M | Purchase |
| 2024-11-20 | THOMPSON JAYE L | Officer | 264.15K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 350.14K | 4.26M | 2.66% |
| 2024-09-29 | Vanguard Group Inc | 273.52K | 3.33M | 2.08% |
| 2024-09-29 | Geode Capital Management, LLC | 133.55K | 1.62M | 1.02% |
| 2024-09-29 | Credit Agricole S.A. | 87.00K | 1.06M | 0.66% |
| 2024-09-29 | Northern Trust Corporation | 74.50K | 905.92K | 0.57% |
| 2024-09-29 | State Street Corporation | 71.41K | 868.32K | 0.54% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 153.46K | 1.87M | 1.17% |
| 2024-10-30 | iShares Russell 2000 ETF | 141.70K | 1.72M | 1.08% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 71.31K | 867.14K | 0.54% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 61.70K | 750.22K | 0.47% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 50.66K | 616.04K | 0.39% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 32.22K | 391.76K | 0.25% |